Business Context and Reporting Period
Company: NeuroOne Medical Technologies Corp (NMTC)
Filing Type: Form 8-K (Current Report)
Date of Report: October 6, 2025
Reporting Period: Fiscal Year ended September 30, 2025
Context: The Company issued a press release announcing preliminary, unaudited financial results for the fiscal year. These results are subject to final review by management and the audit committee.
Key Financial Metrics
- Total Product Revenue: Approximately $9.1 million for the fiscal year ended September 30, 2025.
- Cash and Cash Equivalents: Approximately $6.6 million as of September 30, 2025.
- Profit, Margins, and Debt: The filing text does not provide clear values for net income, operating margins, or debt levels.
- Cash Flow: The filing text does not provide clear values for operating, investing, or financing cash flows.
Material Changes
The filing text does not provide comparative data for the prior fiscal year or quarter to determine material changes in revenue, profit, or liquidity.
Guidance, Outlook, and Risks
Outlook and Guidance: The filing contains forward-looking statements regarding revenue results, financial outlook, product demand, and growth expectations. However, no specific numerical guidance for future periods is provided in this text.
Risks and Contingencies: Management highlighted several risks that could cause actual results to differ materially from expectations, including:
- Compliance with Nasdaq continued listing requirements.
- Success of strategic partnerships and commercialization efforts.
- Supply chain disruptions and labor shortages.
- Performance of technology in pre-clinical and clinical trials.
- Capital requirements and ability to raise additional funds.
- Reimbursement coverage and regulatory decisions.
- Intellectual property protection.
Unusual Items: The financial results presented are preliminary and unaudited. They have not been examined by independent auditors and are subject to revision.
Investor Verification Checklist
- Verify the final audited financial statements for the fiscal year ended September 30, 2025, once released.
- Confirm the Company's compliance status with Nasdaq listing requirements.
- Monitor updates on clinical trial results and regulatory approvals for the Company's technology.
- Assess the Company's capital position and plans for future fundraising given the $6.6 million cash balance.
- Review the full press release (Exhibit 99.1) for any additional operational details not summarized in the 8-K.